Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 1/7/2020
SIETES contiene 93059 citas

 
 
 1 a 20 de 267 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020:18 de mayo. [Ref.ID 103656]
2. Cita con resumen
Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]
3.Enlace a cita original Cita con resumen
Hurley R. Medical cannabis: no NHS patients have benefited from law change, say campaigners. BMJ 2019;364:15 de febrero. [Ref.ID 103033]
4. Cita con resumen
Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679-86. [Ref.ID 102138]
5. Cita con resumen
Anónimo. Inflectra - An infliximab biosimilar. Med Lett Drugs Ther 2017;59:23-5. [Ref.ID 101422]
6. Cita con resumen
Anónimo. Ustekinumab (Stelara) for Crohn's disease. Med Lett Drugs Ther 2017;59:5-6. [Ref.ID 101387]
7. Cita con resumen
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao L-L, MIao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel J-F, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P, for the UNITI-IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2016;375:1946-60. [Ref.ID 100991]
8. Cita con resumen
Anónimo. FDA approves ustekinumab for adults with moderate to severe Crohn’s. DIA Daily 2016:2. [Ref.ID 100758]
9. Cita con resumen
Anónimo. EMA committee recommends approval of ustekinumab for Crohn’s. DIA Daily 2016:2. [Ref.ID 100685]
10. Cita con resumen
Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M, Satsangi J, Danese S, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatici A, Littlewood T, Onida F, Schanz U, Vermeire S, Colombel J-F, Jouet J-P, Clark E, Saccardi R, Tyndall A, Travis S, Farge D. Autologous hepatopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA 2015;314:2524-34. [Ref.ID 99796]
11. Cita con resumen
Khanna R, Bressler B, Levesque BG, Zou G, Sitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, Macintosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG, REACT Study Investigators. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825-34. [Ref.ID 99669]
12. Cita con resumen
McCall C. Momentum grows for medical use of cannabis. Lancet 2015;386:1615-6. [Ref.ID 99633]
13. Cita con resumen
Anónimo. Védolizumab. Prescrire 2015;35:263-4. [Ref.ID 99125]
14.Tiene citas relacionadas Cita con resumen
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Gibson PR, Sparrow M, Leong RW, Florin TH, Gearry RB, Radford-Smith G, Macrae FA, Debinski H, Selby W, Kronborg I, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV. Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015;385:1406-17. [Ref.ID 99034]
15.Tiene citas relacionadas
Ananthakrishnan AN. Surgery for Crohn's disease: look harder, act faster. Lancet 2015;385:1370-1. [Ref.ID 99031]
16. Cita con resumen
Anónimo. Vedolizumab (Entyvio) for inflammatory bowel disease. Med Lett Drugs Ther 2014;56:86-8. [Ref.ID 98222]
17. Cita con resumen
Anónimo. Drugs for inflammatory bowel disease. Med Lett Drugs Ther 2014;56:59-66. [Ref.ID 98172]
18.Enlace a cita original
19. Cita con resumen
Anónimo. Antibiotiques dans l'enfance et maladie intestinale inflammatoire?. Prescrire 2014;34:354-5. [Ref.ID 97563]
20. Cita con resumen
Anónimo. Medicine to treat colitis, Crohn’s disease gets FDA nod. DIA Daily 2014:21 de mayo. [Ref.ID 97520]
Seleccionar todas
 
 1 a 20 de 267 siguiente >>